197 related articles for article (PubMed ID: 35547769)
21. Oncolytic immunotherapy: multiple mechanisms of oncolytic peptides to confer anticancer immunity.
Tang T; Huang X; Zhang G; Liang T
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851309
[TBL] [Abstract][Full Text] [Related]
22. Anti-PD-L1 F(ab) Conjugated PEG-PLGA Nanoparticle Enhances Immune Checkpoint Therapy.
Lee CK; Atibalentja DF; Yao LE; Park J; Kuruvilla S; Felsher DW
Nanotheranostics; 2022; 6(3):243-255. PubMed ID: 35145835
[No Abstract] [Full Text] [Related]
23. MMP-2 Responsive Peptide Hydrogel-Based Nanoplatform for Multimodal Tumor Therapy.
Zhang Q; Hu W; Guo M; Zhang X; Zhang Q; Peng F; Yan L; Hu Z; Tangthianchaichana J; Shen Y; Hu H; Du S; Lu Y
Int J Nanomedicine; 2024; 19():53-71. PubMed ID: 38187906
[TBL] [Abstract][Full Text] [Related]
24. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
[TBL] [Abstract][Full Text] [Related]
25. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy.
Li Q; Su R; Bao X; Cao K; Du Y; Wang N; Wang J; Xing F; Yan F; Huang K; Feng S
Acta Biomater; 2022 May; 144():109-120. PubMed ID: 35314366
[TBL] [Abstract][Full Text] [Related]
26. Fish oil-based microemulsion can efficiently deliver oral peptide blocking PD-1/PD-L1 and simultaneously induce ferroptosis for cancer immunotherapy.
Yang X; Li W; Li S; Chen S; Hu Z; He Z; Zhu X; Niu X; Zhou X; Li H; Xiao Y; Liu J; Sui X; Chen G; Gao Y
J Control Release; 2024 Jan; 365():654-667. PubMed ID: 38030081
[TBL] [Abstract][Full Text] [Related]
27. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
[TBL] [Abstract][Full Text] [Related]
28. Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD-L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment.
Hei Y; Chen Y; Li Q; Mei Z; Pan J; Zhang S; Xiong C; Su X; Wei S
Small; 2022 Mar; 18(9):e2105118. PubMed ID: 34915595
[TBL] [Abstract][Full Text] [Related]
29. Designing Peptide-Based Nanoinhibitors of Programmed Cell Death Ligand 1 (PD-L1) for Enhanced Chemo-immunotherapy.
Xie F; Tang S; Zhang Y; Zhao Y; Lin Y; Yao Y; Wang M; Gu Z; Wan J
ACS Nano; 2024 Jan; 18(2):1690-1701. PubMed ID: 38165832
[TBL] [Abstract][Full Text] [Related]
30. Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma.
Tan X; Wang C; Zhou H; Zhang S; Liu X; Yang X; Liu W
J Nanobiotechnology; 2023 Jun; 21(1):183. PubMed ID: 37291573
[TBL] [Abstract][Full Text] [Related]
31. Combination treatment with immunogenic and anti-PD-L1 polymer-drug conjugates of advanced tumors in a transgenic MMTV-PyMT mouse model of breast cancer.
Li L; Wang J; Radford DC; Kopeček J; Yang J
J Control Release; 2021 Apr; 332():652-659. PubMed ID: 33607175
[TBL] [Abstract][Full Text] [Related]
32. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
33. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
34. APDL1-CART cells exhibit strong PD-L1-specific activity against leukemia cells.
Peng Q; Zhu X; Li C; Xin P; Zheng Y; Liu S
Aging (Albany NY); 2021 Feb; 13(5):7199-7210. PubMed ID: 33653969
[TBL] [Abstract][Full Text] [Related]
35. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
[TBL] [Abstract][Full Text] [Related]
36. Oncolytic adenovirus H101 ameliorate the efficacy of anti-PD-1 monotherapy in colorectal cancer.
Huang L; Zhao H; Shan M; Chen H; Xu B; He Y; Zhao Y; Liu Z; Chen J; Xu Q
Cancer Med; 2022 Dec; 11(23):4575-4587. PubMed ID: 35762456
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
38. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
39. Rise of PD-L1 expression during metastasis of colorectal cancer: Implications for immunotherapy.
Wang HB; Yao H; Li CS; Liang LX; Zhang Y; Chen YX; Fang JY; Xu J
J Dig Dis; 2017 Oct; 18(10):574-581. PubMed ID: 28851046
[TBL] [Abstract][Full Text] [Related]
40. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer.
Chung SY; Chang YC; Hsu DS; Hung YC; Lu ML; Hung YP; Chiang NJ; Yeh CN; Hsiao M; Soong J; Su Y; Chen MH
Neoplasia; 2023 Jan; 35():100856. PubMed ID: 36442297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]